English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/160069
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis

Other TitlesCDH17 RGD antibodies inhibit cancer metastasis [Running title]
AuthorsBartolomé, Rubén Álvaro ; Aizpurua, Carmen; Jaén, Marta; Torres, Sofía ; Calviño, Eva ; Imbaud, Juan Ignacio; Casal, J. Ignacio
KeywordsMonoclonal antibodies
RGD
CDH17
VE-cadherin
α2β1 integrin
Metastasis
Issue Date15-Jan-2018
PublisherAmerican Association for Cancer Research
CitationClin Cancer Res. 24(2):433-444 ( 2018)
AbstractPurpose: New targets are required for the control of advanced metastatic disease. We investigated the use of cadherin RGD motifs, which activate the α2β1integrin pathway, as targets for the development of therapeutic monoclonal antibodies (mAb).
Experimental Design: Cadherin 17 (CDH17) fragments and peptides were prepared and used for immunization and antibody development. Antibodies were tested for inhibition of β1 integrin and cell adhesion, proliferation, and invasion assays using cell lines from different cancer types (colorectal, pancreatic, melanoma, and breast cancer). Effects of the mAbs on cell signaling were determined by Western blot analysis. Nude mice were used for survival analysis after treatment with RGD-specific mAbs and metastasis development.
Results: Antibodies against full-length CDH17 failed to block the binding to α2β1 integrin. However, CDH17 RGD peptides generated highly selective RGD mAbs that blocked CDH17 and vascular-endothelial (VE)-cadherin-mediated β1 integrin activation in melanoma and breast, pancreatic, and colorectal cancer cells. Antibodies provoked a significant reduction in cell adhesion and proliferation of metastatic cancer cells. Treatment with mAbs impaired the integrin signaling pathway activation of FAK in colorectal cancer, of JNK and ERK kinases in colorectal and pancreatic cancers, and of JNK, ERK, Src, and AKT in melanoma and breast cancer. In vivo, RGD-specific mAbs increased mouse survival after inoculation of melanoma and colorectal cancer cell lines to cause lung and liver metastasis, respectively.
Conclusions: Blocking the interaction between RGD cadherins and α2β1 integrin with highly selective mAbs constitutes a promising therapy against advanced metastatic disease in colon cancer, melanoma, and, potentially, other cancers.
Description37 p.-6 fig.
Publisher version (URL)http://dx.doi.org/10.1158/1078-0432.CCR-17-1444
URIhttp://hdl.handle.net/10261/160069
DOI10.1158/1078-0432.CCR-17-1444
ISSN1078-0432
E-ISSN1557-3265
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
CCR_Monoclonal antibodies_2018.pdfPostprint3,58 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.